CombiMatrix Corporation (Nasdaq:CBMX), a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized, today announced the appointment of Mark McGowan to the company's Board of Directors.
Mark P. McGowan is the managing member of SAF Capital Management LLC, a value-oriented investment firm which he founded in November 2006. Prior to forming SAF Capital Management LLC, Mr. McGowan was Co-founder and Managing Partner of MPG Capital Management LLC, an equity market research firm which derived and licensed statistically validated algorithmic trading models and investment strategies for wealthy individuals and institutional investors. Mr. McGowan previously worked within the Consumer and Market Knowledge function of Procter & Gamble, where he was instrumental in shaping marketing strategies for multiple brands, as well as leading Market Mix Modeling and the development of macroeconomic forecasting capabilities within Procter & Gamble's Homecare division. Mr. McGowan performed two cooperative assignments with Johnson & Johnson; working within global operations for Johnson & Johnson subsidiary Ethicon Endo Surgery and in domestic operations for Johnson & Johnson's Consumer Products headquarters. Mr. McGowan received his Bachelor of Science in Microbiology, with a focus in Genomics and Molecular Genetics, from Michigan State University.
"We are pleased to have Mark join our Board at a time when CombiMatrix can benefit from his background in marketing, strategy, and analytics at firms like P&G and Johnson & Johnson," stated Dr. Amit Kumar, President and CEO of CombiMatrix. "Mark brings a fresh perspective to the company with his finance expertise, as well as his operational experience at some of the most respected companies in the world."
"The advancement and adoption of genetic sciences will play an increasingly significant role in the future diagnosis, prognosis and treatment of cancer and other diseases," stated Mr. McGowan. "The comparative advantages of CombiMatrix's molecular diagnostics technology provide an opportunity for the company to become a vanguard within the field of personalized medicine. I look forward to working in conjunction with CombiMatrix leadership as we seek to commercialize these socially important assets while maximizing intrinsic value on a per share basis for company stakeholders."
CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. Combimatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory. Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials.